John K. Chan

19.9k total citations · 7 hit papers
277 papers, 11.9k citations indexed

About

John K. Chan is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, John K. Chan has authored 277 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Reproductive Medicine, 102 papers in Oncology and 93 papers in Obstetrics and Gynecology. Recurrent topics in John K. Chan's work include Ovarian cancer diagnosis and treatment (125 papers), Endometrial and Cervical Cancer Treatments (88 papers) and Uterine Myomas and Treatments (30 papers). John K. Chan is often cited by papers focused on Ovarian cancer diagnosis and treatment (125 papers), Endometrial and Cervical Cancer Treatments (88 papers) and Uterine Myomas and Treatments (30 papers). John K. Chan collaborates with scholars based in United States, China and Taiwan. John K. Chan's co-authors include Daniel S. Kapp, Kathryn Osann, Jacob Y. Shin, Bradley J. Monk, Michael K. Cheung, Jonathan S. Berek, Amreen Husain, Nelson N.H. Teng, Wah Cheuk and William Y.W. Tsang and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

John K. Chan

264 papers receiving 11.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocality

2003 572 citations John K. Chan et al. profile →
Inherited Mutations in Women With Ovarian Carcinoma

2015 503 citations Mark F. Brady, John K. Chan et al. profile →
Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

2006 482 citations Chad A. Hamilton, Kathryn Osann et al. profile →
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

2017 406 citations Robert L. Coleman, Mark F. Brady et al. profile →
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

2019 377 citations Kathleen N. Moore, David S. Miller et al. profile →
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

2016 250 citations John K. Chan, Mark F. Brady et al. profile →
Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017

2022 94 citations Cheng-I Liao, Daniel S. Kapp et al. profile →

Peers

Countries citing papers authored by John K. Chan

Since Specialization

Citations

This map shows the geographic impact of John K. Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John K. Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John K. Chan more than expected).

Fields of papers citing papers by John K. Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John K. Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John K. Chan. The network helps show where John K. Chan may publish in the future.

Co-authorship network of co-authors of John K. Chan

This figure shows the co-authorship network connecting the top 25 collaborators of John K. Chan. A scholar is included among the top collaborators of John K. Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John K. Chan. John K. Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial 2025 ·Clinical Cancer Research ·Jung‐Min Lee, Austin Miller, Peter G. Rose, Mariam AlHilli, (unknown), Veena S. John, (unknown), Koji Matsuo, Jean Siedel, David S. Miller, (unknown), (unknown), John K. Chan, Leslie Bradford, Christopher B. Morse, Christa Nagel, Kerry J. Rodabaugh, Elise C. Kohn, Kathleen N. Moore, Joyce F. Liu	1
2	LBA45 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor 2025 ·Annals of Oncology ·(unknown), (unknown), John K. Chan, June‐Yong Lee, Mariana Scaranti, (unknown), Carolyn Y. Muller, Linda Mileshkin, Toon Van Gorp, Lyndsay Willmott, Ana Santaballa Bertrán, Elizabeth Munro, (unknown), (unknown), (unknown), Giuseppa Scandurra, Ròbert Póka, (unknown), Birendra Kumar Yadav, (unknown)	0
3	Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States 2024 ·Cancers ·(unknown), Chunqiao Tian, Chad A. Hamilton, Michael Richardson, John K. Chan, Daniel S. Kapp, Charles A. Leath, Yovanni Casablanca, (unknown), (unknown), Ann H. Klopp, Craig D. Shriver, Christopher M. Tarney, Nicholas W. Bateman, Thomas P. Conrads, G. Larry Maxwell, Neil T. Phippen, Kathleen M. Darcy	1
4	Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study 2024 ·JCO Precision Oncology ·Gordan Srkalović, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, Eugene R. Ahn, (unknown), John K. Chan, Inderjit Mehmi, (unknown), (unknown), (unknown), Harshraj Leuva, Ramya Thota, (unknown), (unknown), (unknown), Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky	1
5	Endometrial cancer and obesity trends in the United States in the 21st century. 2024 ·Journal of Clinical Oncology ·(unknown), Cheng-I Liao, Jenny Chang, (unknown), (unknown), Krishnansu S. Tewari, Daniel S. Kapp, John K. Chan, Robert E. Bristow	1
6	Increase in uterine cancer incidence among Black patients in the United States: A United States Cancer Statistics Study of nearly 95,000 patients from 2001 to 2019 2024 ·Gynecologic Oncology ·(unknown), Cheng-I Liao, (unknown), C. A. Johnson, Ritu Salani, Daniel S. Kapp, John K. Chan	1
7	Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey 2023 ·Cancer Control ·Michael Richardson, Kristopher Attwood, Gabriella Smith, Su‐Ying Liang, (unknown), Krishnansu S. Tewari, Robert L. Coleman, Daniel S. Kapp, John K. Chan, Bradley J. Monk	6
8	Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study 2023 ·JCO Precision Oncology ·Eugene R. Ahn, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, (unknown), John K. Chan, Michael L. Maitland, (unknown), (unknown), Ani Sarkis Balmanoukian, Charles W. Drescher, Rui Li, Apostolia M. Tsimberidou, Charles A. Leath, (unknown), (unknown), Susan Halabi, Richard L. Schilsky	12
9	Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. 2023 ·Journal of Clinical Oncology ·Gordan Srkalović, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, Eugene R. Ahn, (unknown), John K. Chan, Inderjit Mehmi, (unknown), (unknown), (unknown), Harshraj Leuva, Ramya Thota, Kathleen J. Yost, (unknown), (unknown), Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky	0
10	Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance 2020 ·Gynecologic Oncology ·John K. Chan, Su‐Ying Liang, Daniel S. Kapp, (unknown), (unknown), Thomas J. Herzog, Robert L. Coleman, Bradley J. Monk, Michael Richardson	2
11	818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study 2020 ·Annals of Oncology ·Aikou Okamoto, Gini F. Fleming, Michael A. Bookman, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Noelle Cloven, Takayuki Enomoto, David M. O’Malley, Linda Van Le, Krishnansu S. Tewari, Joyce N. Barlin, William H. Bradley, Kathleen N. Moore, John K. Chan, Meijing Wu, (unknown), Minh H. Dinh, Robert L. Coleman, Carol Aghajanian	2
12	CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study 2017 ·Clinical Cancer Research ·Chaan S. Ng, Zheng Zhang, Susanna I. Lee, Helga S. Marques, (unknown), Feng Su, (unknown), Robert S. Mannel, Joan L. Walker, Warner K. Huh, Stephen C. Rubin, Paul DiSilvestro, Lainie P. Martin, John K. Chan, Michael A. Bookman, Robert L. Coleman, Ting-Yim Lee	20
13	Factors associated with oophorectomy in children with benign ovarian masses 2017 ·International Journal of Gynecology & Obstetrics ·Daniel S. Kapp, (unknown), (unknown), John K. Chan, (unknown), (unknown)	1
14	Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia 2016 ·Obstetrics and Gynecology ·Raymond Osborne, Virginia L. Filiaci, Julian C. Schink, Robert S. Mannel, Kian Behbakht, James Hoffman, Nick M. Spirtos, John K. Chan, John Tidy, David S. Miller	41
15	The influence of age and other prognostic factors associated with survival of ovarian immature teratoma — A study of 1307 patients 2016 ·Gynecologic Oncology ·John K. Chan, Austin B. Gardner, (unknown), (unknown), (unknown), Mark N. Alshak, Daniel S. Kapp	12
16	Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer 2015 ·Obstetrical & Gynecological Survey ·Devansu Tewari, James Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, John K. Chan	2
17	Utilization of and charges for robotic versus laparoscopic versus open surgery for endometrial cancer 2012 ·Journal of Surgical Oncology ·Xinhua Yu, Deirdre Lum, T. Kiet, Katherine C. Fuh, James W. Orr, Rebecca Brooks, Stefanie Ueda, (unknown), Daniel S. Kapp, John K. Chan	28
18	Influence of Gynecologic Oncologists on the Survival of Patients With Endometrial Cancer 2011 ·Journal of Clinical Oncology ·John K. Chan, Alexander E. Sherman, Daniel S. Kapp, (unknown), Kathryn Osann, Larry G. Maxwell, Lee-may Chen, Harshal Deshmukh	78
19	Impact of the Human Papilloma Vaccine on Cervical Cancer 2007 ·Journal of Clinical Oncology ·John K. Chan, Jonathan S. Berek	42
20	Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay–guided chemotherapy 2003 ·American Journal of Obstetrics and Gynecology ·Vera Loizzi, John K. Chan, Kathryn Osann, Fabio Cappuccini, Philip J. DiSaia, Michael L. Berman	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact